Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected mel… Read more
Market Cap & Net Worth: Evaxion Biotech AS (EVAX)
Evaxion Biotech AS (NASDAQ:EVAX) has a market capitalization of $31.94 Million ($31.94 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23928 globally and #8315 in its home market, demonstrating a 18.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evaxion Biotech AS's stock price $3.83 by its total outstanding shares 8340215 (8.34 Million).
Evaxion Biotech AS Market Cap History: 2021 to 2026
Evaxion Biotech AS's market capitalization history from 2021 to 2026. Data shows change from $368.64 Million to $31.94 Million (-47.06% CAGR).
Index Memberships
Evaxion Biotech AS is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #643 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2107 of 3165 |
Weight: Evaxion Biotech AS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evaxion Biotech AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evaxion Biotech AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.11x
Evaxion Biotech AS's market cap is 2.11 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $57.21 Million | $73.00K | -$22.12 Million | 783.75x | N/A |
| 2024 | $7.05 Million | $3.34 Million | -$10.57 Million | 2.11x | N/A |
Competitor Companies of EVAX by Market Capitalization
Companies near Evaxion Biotech AS in the global market cap rankings as of March 18, 2026.
Key companies related to Evaxion Biotech AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Evaxion Biotech AS Historical Marketcap From 2021 to 2026
Between 2021 and today, Evaxion Biotech AS's market cap moved from $368.64 Million to $ 31.94 Million, with a yearly change of -47.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $31.94 Million | -19.71% |
| 2025 | $39.78 Million | +464.23% |
| 2024 | $7.05 Million | -87.68% |
| 2023 | $57.21 Million | -61.35% |
| 2022 | $148.04 Million | -59.84% |
| 2021 | $368.64 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Evaxion Biotech AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.94 Million USD |
| MoneyControl | $31.94 Million USD |
| MarketWatch | $31.94 Million USD |
| marketcap.company | $31.94 Million USD |
| Reuters | $31.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.